629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment and systemic immune response

• Published in: Journal for immunotherapy of cancer Vol. 11; no. Suppl 2; p. A1809
• Main Authors: Saltos, Andreas N, Arrowood, Christy, Beasley, Georgia M, Ronald, James, El-Haddad, Ghassan, Gray, Jhanelle E, Pellini, Bruna, Tanvetyanon, Tawee, Guerra-Guevara, Luiziane, Khan, Uzma, Wolf, Steven, Gu, Lin, Wang, Xiaofei, Zheng, Hong, Foresman, Dana, Yu, Xiaoqing, Cantwell, Mark J, Antonia, Scott J, Beg, Amer A, Ready, Neal E
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.11.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Biopsy; Chemotherapy; Cytokines; Disease control; Immune response; Immunotherapy; Lung cancer; Metastasis; Monoclonal antibodies; Patients; Regular Abstracts – Part 2; Tumors

BackgroundMEM-288 is a conditionally replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust dendritic cell (DC)-mediated systemic T-cell responses capable of inhibiting injected and abscopal tumo...